Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (311,656)	$ (217,490)	$ (183,619)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	32,071	23,699	18,078
Amortization and impairment of internal-use software	4,427	2,449	2,168
Stock-based compensation expense	116,017	57,933	88,425
Change in fair value of warrant liabilities	0	(32,989)	0
Impairment of long-lived assets	10,126	0	0
Other	77	85	(819)
Changes in operating assets and liabilities:
Accounts receivable, net	1,483	(899)	3,912
Inventories	542	(4,262)	7,884
Deferred cost of revenue	2,325	(2,219)	1,163
Prepaid expenses and other current assets	6,653	(10,077)	2,126
Operating lease right-of-use assets	7,393	7,078	10,288
Other assets	(429)	(1,820)	573
Accounts payable (included related party amounts of $(12,567) and $(4,422), respectively)	(24,573)	22,856	137
Accrued expenses and other current liabilities (included related party amounts of $2,966, $(1,293) and $3,517, respectively)	2,671	8,316	82
Deferred revenue (included related party amounts of $2,572, $(20,959)and $(14,917), respectively)	(418)	(8,799)	(16,210)
Operating lease liabilities	(8,934)	(7,054)	(8,528)
Other liabilities	(3,165)	(3,635)	88
Net cash used in operating activities	(165,390)	(166,828)	(74,252)
Cash flows from investing activities:
Purchases of property and equipment	(4,048)	(3,968)	(4,054)
Purchases of intangible assets		(5,500)
Proceeds from sale of property and equipment	5	1	838
Capitalized internal-use software costs	(7,262)	(4,505)	(3,320)
Cash paid for acquisitions, net of cash acquired		(94,165)
Net cash used in investing activities	(11,305)	(108,137)	(6,536)
Cash flows from financing activities:
Proceeds from issuance of redeemable convertible preferred stock			82,500
Payments for issuance costs of redeemable convertible preferred stock			(232)
Proceeds from exercise of stock options (included related party amounts of zero, zero and $67,359, respectively)	4,203	16,998	76,151
Payments of deferred offering costs	(693)	(30,642)	(3,084)
Proceeds from issuance of common stock upon merger		309,720
Proceeds from PIPE (included related party amounts of zero, $25,000 and zero, respectively)		250,000
Proceeds from exercise of merger warrants		44
Payments for taxes related to net share settlement of equity awards	(197)
Proceeds from issuance of common stock under employee stock purchase plan	6,464
Payment for warrant redemptions		(116)
Net cash provided by financing activities	9,777	546,004	155,335
Effect of exchange rates on cash	385	(146)
Net increase (decrease) in cash and restricted cash	(166,533)	270,893	74,547
Cash and restricted cash—beginning of period	561,755	290,862	216,315
Cash and restricted cash—end of period	395,222	561,755	290,862
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment during the period included in accounts payable and accrued expenses	473	722	535
Stock-based compensation capitalized for internal-use software costs	3,191	1,166	637
Vesting of related party early exercised stock options			91,046
Reclassification of deferred offering costs		3,971
Assumption of merger warrants liability		75,415
Deferred offering costs during the period included in accounts payable and accrued expenses	45		887
Conversion of redeemable convertible preferred stock to common stock		837,351
Redemption/Exercise of Class A Common Stock Warrants		42,354
Stock consideration in acquisition of businesses, including fair value of common stock issued and fair value of stock-based awards that were vested		322,842
Cash and cash equivalents	386,849	553,182	282,489
Restricted cash, current	1,399	1,599	1,399
Restricted cash, noncurrent	6,974	6,974	6,974
Cash and cash equivalents	386,849	553,182
Total cash, cash equivalents and restricted cash	$ 395,222	$ 561,755	$ 290,862